Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2014

View Archived Issues

Preclinical safety of [18F]FBYBF-2 validates dosimetric studies in humans

Sterna Biologicals presents first-in-class GATA-3-targeting DNAzymes

Preclinical and clinical data reported for PI3K-alpha kinase inhibitor in various cancers

Merck Serono and MorphoSys collaborate on immune-oncology

Horizon Discovery licenses CRISPR gene editing system

CQDM and Sanofi Canada form drug discovery partnership

Hyperion Therapeutics acquires Andromeda Biotech

AnGes signs agreement with Quintiles for phase III study of Collategene

Circassia discloses positive data from phase IIb dust mite allergy trial

ViiV Healthcare and Janssen to develop single-tablet regimen for HIV

FDA removes clinical hold on imetelstat myelofibrosis trial

Oncobiologics begins phase I trial of biosimilar ONS-3010

Bayer Schering Pharma discloses novel Mnk1 inhibitors

Parion and Santen sign option agreement for P-321 in Asia

EntreMed changes name

Phase I results on OPB-51602 in relapsed/refractory hematological malignancies

Boehringer Ingelheim patents BRD4 inhibitors

Esteve patent describes novel sigma1 receptor ligands

Merck & Co. prepares and tests novel PDE10A inhibitors

OncoMed halts enrollment and dosing in phase I trials of vantictumab and Fzd8-Fc

FDA approves Lymphoseek for use in head and neck cancer

Roche presents new TRPA1 antagonists

Celgene exercises option to license AG-221 under Agios collaboration

KalGene to collaborate with multiple organizations on biomarker and treatment for aggressive cancers

Phase IIb trial of CRS-207 and GVAX Pancreas vaccines opens for recruiting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...